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Abstract
Vitreous hemorrhages are important clinical manifestations of proliferative diabetic retinopathy. Non-cleared
vitreous hemorrhages could lead to hemosiderosis bulbi and glaucoma. Here, we describe the case of a type 2
diabetic patient presenting anterior segment and vitreous hemorrhages that resolved three days after treatment
with a single intravitreal injection of dobesilate.
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Background
Vitreous hemorrhages are an important clinical mani-
festation of proliferative diabetic retinopathy. A vitreous
hemorrhage may spontaneously get re-absorbed over time
in some cases. However, sometimes it requires a pars plana
vitrectomy to remove the hemorrhage because otherwise it
may lead to retinal tears, retinal detachment, hemosiderosis
bulbi and glaucoma, causing a further reduction in vision
[1, 2]. Here, we report the early efficacy of a single intravit-
real dobesilate injection in reducing vitreous hemorrhages
caused by proliferative diabetic retinopathy.
Case presentation
A 68-year-old Caucasian male with type 2 diabetes pre-
sented with one-month history of intense vision loss in
his right eye. The patient did not seem had suffered any
recent traumatic eye accident in the affected eye. The oph-
thalmic microscopic examination showed a pseudophakic
right eye with both non-recent and recent hemorrhages in
the anterior segment (Fig. 1a). A fundoscopic study re-
vealed a massive vitreous hemorrhage (Fig. 1c). The
intraocular pressure was 50 mmHg, which reduced to
14 mmHg after a paracentesis procedure.
Treatment
After approval by the Institutional Review Board, the pa-
tient signed an informed consent form, which included a
comprehensive description of the off-label use of dobesilate
and the proposed procedure. The patient received an
intravitreal solution of dobesilate (150 μl) under sterile
conditions in his right eye according to the international
guidelines for intravitreal injections [3]. Prophylactic topical
antibiotics were given for 2 days postinjection. Dobesilate
was administered as a 12.5 % solution of diethylammonium
2.5-dihydroxybencenesulfonate (etamsylate, Dicynone®
Sanofi-Aventis. Paris. France). No ocular side effects
were observed upon the administration of dobesilate or
during the following days. Three days after the treatment,
the hemorrhage in the anterior segment (Fig. 1b) had com-
pletely cleared. An obvious improvement was also ap-
preciated in that of the vitreous cavity (Fig. 1d). Vision
improvement was also observed. While the vision of
the right eye was completely lost before the treatment
was administered, the visual acuity determined by the
Snellen chart became 0.4 three days after the treat-
ment. The intraocular pressure remained normal.
Discussion
A vitreous hemorrhage is a common disease that accom-
panies a wide variety of ophthalmological pathologies. The
most common causes include proliferative diabetic retinop-
athy, vitreous detachment with or without retinal breaks,
and trauma. Less common causes include vascular occlu-
sive disease, retinal arterial aneurysms, hemoglobinopathies,
neovascular age-related macular degeneration, and intraoc-
ular tumors. Hemorrhage into the vitreous gel results in
rapid clot formation and is followed by a slow clearance of
approximately 1 % per day [3]. The complications of persis-
tant vitreous hemorrhages are hemosiderosis bulbi and
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glaucoma. The treatment option for non-clearing vitreous
hemorrhage is a pars plana vitrectomy.
Dobesilate has been used for many years for the treat-
ment of diabetic retinopathy. Its mechanism of action has
not been established, but several possibilities have been
proposed, including anti-inflammatory effects and inhib-
ition of vascular endothelial growth factor (VEGF) [4, 5].
Although we cannot rule out the participation of these
mechanisms, dobesilate clinical benefits for treatment of
vitreous hemorrhage, probably should be largely attributed
to its ability to inhibit the activity of fibroblast growth
factor (FGF) that has been recently demonstrated [6]. FGF
was the first inductor of vasculogenesis, proliferation of
endothelial cells, and vascular permeability that was
described [7]. Later, it was shown to be a broad-spectrum
mitogen [8]. Recent data show that it should be better
considered an inflammation-triggering and inflammation-
sustaining protein, the mitogenic and permeability-
inducing activities being manifestations of its inflam-
matory activity [9, 10]. The substantial increase in the
permeability of the newly generated vessels has been attrib-
uted to FGF, which accumulates at high levels during dia-
betic retinopathy. In the case of hemorrhages, extravasated
blood cells, such as monocyte-derived macrophages, also
synthesize FGF [11]. FGF can also induce the expression of
cyclooxygenase-2 (COX-2) and phospholipase A2, as well
as the ensuing production of prostaglandins in endothelial
cells, thereby creating a positive feedback loop that favors
chronic bleeding and inflammation in a vicious cycle [12–
16]. It has been reported that high levels of FGF induce
structural changes in intestinal vessels, resulting in the de-
velopment of lethal intestinal hemorrhages [17], and in
FGF-induced corneal neovascularization, resulting in
hyphemas [18]. We have previously shown that neovascular
growth with its subsequent bleeding can be suppressed by
inhibiting FGF [19]. Forty-four years ago, orally adminis-
tered dobesilate was used to treat vitreous hemorrhage
in diabetic patients with unclear efficacy [20]. This is
likely due to the route of administration that does not
allow dobesilate to reach adequate concentrations in
the eye, as previously discussed [21]. Furthermore, we
have recently reported that an intravitreal injection of
dobesilate displayed clinical efficacy in a patient with a
submacular hemorrhage secondary to age-related macular
degeneration [22]. Here, we describe the dramatic clear-
ance of a vitreous hemorrhage in a diabetic patient after a
Fig. 1 Efficacy of an intravitreal dobesilate injection to clear a vitreous hemorrhage in a diabetic patient. Photographs A and C were taken at
presentation, and B and D were taken after 3 days of treatment. The non-recent and recent hemorrhages viewed at the presentation in the
anterior segment (a) resolved after the treatment (b). At the presentation (c) the fundoscopy showed a blurred view of the retina caused by
bleeding at the vitreous. After treatment (d), a clear view to the retina with residual blood was depicted. Note in B the abnormal appearance
of the pupil due to luxation of the lens. The arrow indicates the paracentesis site
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single intravitreal injection of dobesilate, which is a repre-
sentative case of five patients who show similar thera-
peutic outcomes. Our study seems to be in full agreement
with the use of etamsylate for the treatment of periven-
tricular hemorrhages in infants with very low birth weight.
Prophylactic treatment has also been shown to reduce
intraventricular bleeding in babies of less than 34-weeks
of gestation [23].
The data shown in this report seems support that direct
application of dobesilate (a drug with a long history of
clinical safety that was recently re-discovered as an FGF
inhibitor) could serve as a promising new clinical applica-
tion to temper the most important pathological effects of
vitreous hemorrhages in proliferative diabetic retinopathy.
Conclusion
An intravitreal injection of dobesilate for the treatment
of vitreous hemorrhages related to proliferative diabetic
retinopathy is associated with prompt morphologic and
visual improvement and may offer benefits over the nat-
ural course of the disease.
Consent
Written informed consent for publication of the clinical
details and images was obtained from the patient.
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